Alessa Therapeutics Announces IND Clearance to Collaborate with the National Cancer Institute

Alessa Therapeutics, Inc., a clinical-stage drug development company founded by University of California, San Francisco professor Dr. Pamela Munster, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) for Biolen®. Alessa, in collaboration with the Radiation Oncology Branch of the National Cancer Institute (NCI), will initiate a Phase 1 clinical study of Biolen in conjunction with radiation therapy.

MORE